Minimally Invasive Foot Implant by GraMedica® Offers Innovative Treatment Option for Faulty Foot Mechanics.
The findings of a recent study on the HyProCure® talotarsal fixation device have been published in the Journal of Foot & Ankle Surgery (JFAS 50 (2011) 551-557). The purpose of this research, “Radiographic Evaluation of Navicular Position in the Sagittal Plane- Correction Following an Extra-osseous Talotarsal Stabilization Procedure,” was to evaluate the effect of HyProCure® on stabilizing the inner arch of the foot. A secondary question was also answered by this study as to whether collapse of the arch occurs as a direct result of the ankle bone (talus) dislocating on the hindfoot bones or if it is the other way around, the ankle bone dislocates due to the drop of the inner arch. The findings of this study showed that once the ankle bone was repositioned back to its normal position on the heel bone and stabilized by HyProCure®, there was restoration of arch height. Furthermore, the correction to the inner arch was maintained over time. The data for the study was collected by a retrospective x-ray analysis by Dr. Michael E. Graham, podiatric surgeon and inventor of the HyProCure® device.
“When the arch of the foot collapses, this places tremendous strain on the ligaments and tendons on the inner-side of the foot. Eventually these structures become painful, indicating that something is wrong. Previous treatments were mainly aimed at decreasing the pain to the ligaments or tendons and, of course, trying to decrease the strain placed on these structures,” said Graham. “Arch supports are commonly used to try to decrease the amount of arch drop but there is little evidence to show arch supports are actually able to maintain the arch.” Where external devices such as arch supports remain questionable in offering a cure, internally placed HyProCure® has now provided that evidence.
HyProCure® effectively improved the anatomic alignment of the ankle bone on the hindfoot bones. In addition, HyProCure® showed statistically significant improvement in the maintenance of arch height in the foot. This theoretically represents a decrease of excessive forces acting on the ligaments and tendons. More research on the reduction of forces acting on those tissues has been performed and is awaiting publication.
Read more at http://hyprocure.com/publications/research-articles/.
The first true talotarsal stabilization device, anatomically designed to permanently correct partial talotarsal dislocation (TTDS). If you are suffering from foot, ankle, leg, knee, or hip pain, or even flat feet, you may be experiencing the effects of Partial TaloTarsal Dislocation Syndrome (TTDS). To learn more about TTDS, visit http://www.hyprocure.com/. Find a HyProCure® trained doctor in your area at http://hyprocure.com/doctorlocator.php
Showing posts with label GraMedica. Show all posts
Showing posts with label GraMedica. Show all posts
Wednesday, November 14, 2012
Sunday, October 14, 2012
New EOTTS Classification System Identifies HyProCure® as Having Better Design and Patient Outcomes
A recent study, Extra-Osseous Stabilization Devices: A New Classification System published in The Journal of Foot and Ankle Surgery, Volume 51, Issue 5, Pages 613-619, September 2012, provides a systematic approach to classifying the differences in design features and biomechanical function of Extra-Osseous TaloTarsal Stabilization (EOTTS) devices.
Read more >>>
To read the abstract of this study and find further research on the positive outcomes of EOTTS with HyProCure® visit the library section of http://www.GraMedica.com/.
Read more >>>
To read the abstract of this study and find further research on the positive outcomes of EOTTS with HyProCure® visit the library section of http://www.GraMedica.com/.
Saturday, October 6, 2012
Leading Chinese Foot and Ankle Surgeon Bestowed Title of GIII® 2012 “Game Changer”
The Game Changer Award is an esteemed recognition given by GIII® and GraMedica® to an individual who demonstrates a strong dedication and passion to improve the quality of life for patients suffering from the ill-effects of foot pathologies and who helps elevate the field of foot and ankle surgery.GIII® and GraMedica® are pleased to recognize Dr. Zhang for his hard work and will continue to support his future endeavors to educate Chinese foot and ankle specialists on the treatment of foot and ankle conditions.
Read more.
Friday, October 5, 2012
Chinese Surgeons Trained in use of HyProCure® at 2012 TongRen Foot and Ankle Symposium
Specialists in attendance at China’s leading Foot and Ankle Symposium gained valuable education on the Extra-Osseous TaloTarsal Stabilization Procedure.
“The room was packed with surgeons, all with their cameras and video cameras, eager for their first foot cadaver course,” said Michael E. Graham, DPM, FACFAS, FAENS, founder of GraMedica® and creator of HyProCure®. “It was amazing to be involved in such a ground-breaking event.” Read more.
Thursday, October 4, 2012
Changing Lives, One Step at a Time: HyProCure® Marks 8 Years
Over the past eight years, HyProCure®, a Type II Extra-Osseous TaloTarsal Stabilization (EOTTS) device, has become the leading solution for patients suffering with the symptoms and secondary conditions resulting from partial talotarsal dislocation. TaloTarsal Displacement is a foot imbalance that throws both the foot and the entire body out of alignment. It affects people of all ages and is often the direct or contributing cause of overpronation, bunions, plantar fasciitis, knee pain, hip pain, back pain, and even problems in the neck and shoulders. Read more.
Creator of HyProCure® Educates Foot & Ankle Specialists Across China
In a recent journey throughout China, innovator of the life changing HyProCure® procedure took time to educate surgeons, meet with patients and share his skills. Read more.
Saturday, September 15, 2012
HyProCure® Classified as a Type II EOTTS Device: Improved Design and Function
New Published Research on the EOTTS with HyProCure® Procedure.
The Journal of Foot & Ankle Surgery Article, September 2012
Extra-Osseous Stabilization Devices: A New Classification System. Visit http://www.jfas.org/article/S1067-2516(12)00242-6/abstract for the article abstract.
Key Conclusions:
- It has been acknowledged that a device that better matches the anatomical shape of the tarsal sinus and follows its natural orientation would allow for better biomechanical functioning.
- Only Type II devices (HyProCure®) meet the ideal parameters,which has an impact on their improved success rates.
- This improved design and function may also contribute to the success of Type II (HyProCure®) devices in decreasing the effects of or even eliminating secondary pathologies.
Friday, July 20, 2012
HyProCure® Expands Global Reach: Now Available to Patients in Italy
Three EOTTS with HyProCure® procedures were recently performed in Italy, intiating the device into the country. Three surgeons, Prof. La Rosa of “Bambino Gesu,” the Vatican’s Pediatric Hospital in Rome, Prof. Giglio and MD Offiano each offered this revolutionary treatment option to their patients.
Read More:
HyProCure® Expands Global Reach: Now Available to Patients in Italy
Subscribe to:
Comments (Atom)